Results 291 to 300 of about 118,448 (336)
Equine Veterinary Journal, EarlyView.Abstract Background Due to the high frequency of laminitis reported for both conditions, the relationship between pituitary pars intermedia dysfunction (PPID) and insulin dysregulation (ID), and the potential role of dopamine in modifying insulin secretion, requires further investigation.
Nicolas C. Galinelli +7 more
wiley +1 more source
The FEBS Journal, EarlyView.Enhancing endocannabinoid signaling by targeting FAAH effectively mitigates cognitive deficits, reduces amyloid pathology, and modulates neuroinflammatory responses in a preclinical model of Alzheimer's disease. This effect is potentially mediated by attenuating the Aβ‐induced overexpression of the Bace1 gene through CB1‐dependent hypermethylation of ...
Sergio Oddi +12 more
wiley +1 more source
A signal transduction blind spot: the function of adenylyl cyclase transmembrane domains
The FEBS Journal, EarlyView.Transmembrane adenylyl cyclases (tmACs) are essential for synthesising the universal second messenger cyclic AMP. All tmACs share a common topology that includes a large 12‐helix transmembrane (TM) domain. This domain accounts for ~ 35% of the coding sequence but its function is still an open question.
Ryan S. Dowsell, Matthew G. Gold
wiley +1 more source
The FEBS Journal, EarlyView.Here, we generated a DDC‐KO cellular model for studying aromatic amino acid decarboxylase (AADC) deficiency. This model was created using CRISPR‐Cas9 in the SH‐SY5Y neuroblastoma cell line and was validated through the absence of the dopamine product and an altered l‐dopa metabolite profile.
Cristian Andres Carmona‐Carmona +11 more
wiley +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Seminars in Neurology, 2001
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Dopamine agonists provide an effective means of treating early, middle, and late stages of Parkinson's disease. This article outlines the advantages and disadvantages of dopamine agonists as compared with levodopa therapy. The features and costs of the four Food and Drug Administration-approved agonists (bromocriptine, pergolide, pramipexole, and ...
P, Tuite, B, Ebbitt
openaire +2 more sources
Neuroprotection by dopamine agonists
Journal of neural transmission. Supplementum, 1994Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative ...
Lange, Klaus W. +5 more
openaire +4 more sources
Journal of Neural Transmission, 2019
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
P.-A. Löschmann, R. Horowski
openaire +3 more sources
The pioneering work of Arvid Carlsson has laid the foundation for a number of innovative therapies for severe central nervous system (CNS) diseases. He was awarded the Nobel Price for the discovery of the crucial role of dopamine (DA) as a neurotransmitter in the CNS, thereby forming the basis for the symptomatic therapy of Parkinson's disease (PD ...
P.-A. Löschmann, R. Horowski
openaire +3 more sources
Dopamine agonist‐responsive depression [PDF]
Psychogeriatrics, 2013 AbstractDopaminergic dysfunction is implicated in the pathophysiology of treatment‐resistant depression. In this review, we describe the putative role of dopamine in depression, summarize the evidence for the efficacy of dopamine receptor agonists in the treatment of treatment‐resistant depression, and discuss the underlying mechanisms by which these ...
Hiroshi Kunugi, Hiroaki Hori
openaire +2 more sources
Neuroprotection and Dopamine Agonists
2004Parkinson’s disease is a neurodegenerative disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra pars compacta. Accumulating evidence indicates that apoptosis contributes to the cell death in Parkinson’s disease patients’ brain.
Zvezdan Pirtošek, Dušan Flisar
openaire +3 more sources